

1. Johnson, D. M., Johnson, N. L., **Beckwith, C.G.**, Palmieri, P.A., & Zlotnick, C. Rapid human immunodeficiency virus testing and risk prevention in residents of battered women's shelters. *Women's Health Issues*. 2017; 27 (1): 36-42.
2. **Beckwith CG**, Castonguay B, Trezza C, Bazerman L, Patrick R, Cates A, Olsen H, Kurth A, Liu T, Peterson J, Kuo I. Gender differences in HIV care among criminal justice-involved persons: Baseline data from the CARE+ Corrections Study. *PLOS One* 2017; 12(1): e0169078. doi:10.1371/journal.pone.0169078. PMID:28081178.
3. Loeliger KB, Biggs ML, Young R, Seal DW, **Beckwith CG**, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium. *AIDS and Behavior*. 2017. Feb 10;1–13. Available from: <https://link.springer.com/article/10.1007/s10461-017-1722-9>.
4. Christopoulos KA, Cunningham WE, **Beckwith CG**, Kuo I, Golin CE, Knight K, Flynn PM, Spaulding AC, Coffin LS, Kruszka B, Kurth A, Young JD, Mannheimer S, Crane HM, Kahana SY. *AIDS and Behavior*. 2017. doi:10.1007/s10461-017-1804-8.
5. Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, **Beckwith CG**, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. *Substance Abuse Treatment, Prevention, and Policy*. 2017. May 16;12(1):24. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433052/>.
6. Brinkley-Rubinstein L, Rosen DL, Christopher P, Bazerman L, **Beckwith CG**. Long-acting injectable anti-retroviral therapy: An opportunity to improve HIV treatment and reduce HIV transmission among persons being released from prison facilities. *Clinical Infectious Diseases* 2017 [Epub ahead of print May 26]. doi: 10.1093/cid/cix493.
7. Preiksaitis JK, Hayden RT, Tong Y, Pang XL, Fryer JF, Heath AB, Cook L, Petrich AK, Yu B and **Caliendo AM**. Are we there yet? Impact of the 1<sup>st</sup> International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples. *Clin Infectious Diseases*. 2016 Sep 1;63(5):583-9. doi: 10.1093/cid/ciw370. Epub 2016 Jun 15.
8. Hayden RT, Gu Z, Sam SS, Sun Y, Tang L, Pounds S, and **Caliendo AM**. Comparative Performance of Reagents and Platforms for Quantitation of Cytomegalovirus DNA by Digital PCR. *J Clin Micro*. 2016 Oct;54(10):2602-8. doi: 10.1128/JCM.01474-16. Epub 2016 Aug 17.
9. Morton CO, White PL, Barnes RA, Klingspor L, Cuenca-Estrella M, Lagrou K, Bretagne S, Melchers W, Mengoli C, **Caliendo AM**, Cogliati M, Debets-Ossenkopp Y, Gorton R, Hagen F, Halliday C, Hamal P, Harvey-Wood K, Jatton K, Johnson G, Kidd S, Lengerova

- M, Lass-Flörl C, Linton C, Millon L, Morrissey CO, Paholcsek M, Fe Talento A, Ruhnke M, Willinger B, Donnelly JP, Loeffler J, on behalf of the EAPCRI. Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is *Aspergillus*? *Medical Mycology*. 2016. 0:1-12. doi: 10.1093/mmy/myw093.
10. Hayden RT, Sun Y, Tang L, Procop GW, Hillyard DR, Pinsky BA, Young SA and **Caliendo AM**. Progress in Quantitative Viral Load Testing: Variability and Impact of the WHO Quantitative International Standards. *J Clin Micro*. 2017 Feb;55(2):423-430. doi: 10.1128/JCM.02044-16. Epub 2016 Nov 16.
  11. Kaul KL, Sabatini LM, Tsongalis GJ, **Caliendo AM**, Olsen RJ, Ashwood AR, Bale S, Benirschke B, Carlow D, Funke BH, Grody WW, Hayden RT, Hegde M, Lyon E, Murata K, Pessin M, Press RD, Thomson RB. The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. *Academic Pathology* 2017;4:1-21.
  12. Lorenz ML, Bouton TC and **Caliendo AM**. First reported case of vertebral osteomyelitis due to *Erysipelothrix rhusiopathiae*. IDCases 2017; In Press.
  13. Raifman J, Nunn A, Oldenburg CE, Montgomery MC, Almonte A, Agwu AL, Arrington-Sanders R, **Chan PA**. “An Evaluation of a Clinical Pre-Exposure Prophylaxis Education Intervention among Men Who Have Sex with Men.” *Health Serv Res*. 2017 Jul 25.
  14. Chamberlain N, Crosby RA, Mena L, **Chan PA**, Mayer KH. “Is Patient-Reported Exposure a Reliable Indicator for Anogenital Gonorrhea and Chlamydia Screening in Young Black Men Who Have Sex With Men?” *Sex Transm Dis*. 2017 Jul;44(7):390-392.
  15. Glynn TR, Operario D, Montgomery M, Almonte A, **Chan PA**. “The Duality of Oral Sex for Men Who Have Sex with Men: An Examination into the Increase of Sexually Transmitted Infections Amid the Age of HIV Prevention.” *AIDS Patient Care STDS*. 2017 Jun;31(6):261-267.
  16. Patel RR, Mena L, Nunn A, McBride T, Harrison LC, Oldenburg CE, Liu J, Mayer KH, **Chan PA**. “Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention.” *PLoS One*. 2017 May 30;12(5).
  17. Wray T, **Chan PA**, Simpanen E, Operario D. “eTEST: Developing a Smart Home HIV Testing Kit that Enables Active, Real-Time Follow-Up and Referral After Testing.” *JMIR Mhealth Uhealth*. 2017 May 8;5(5).
  18. **Chan PA, Flanigan TP**. Effective HIV Prevention Interventions and the Need for Rapid Mobilization to Address HIV Outbreaks among At-Risk Populations. (2017) *J Infect Dis*. May 15; 215(10): 149102. PMID: 2840707. PMCID: PMC5461425
  19. Montgomery MC, Raifman J, Nunn AS, Bertrand T, Uvin AZ, Marak T, Comella J, Almonte A, **Chan PA**. “Insurance coverage and utilization at a sexually transmitted disease clinic in a Medicaid expansion state.” *Sexually Transmitted Diseases*. 2017 May;44(5):313-317.

20. Moitra, E., LaPlante, A., Armstrong, ML, **Chan, PA**, Stein, MD. "Pilot randomized controlled trial of acceptance-based behavior therapy to promote HIV acceptance, HIV disclosure, and retention in medical care." *AIDS and Behavior*. April 27, 2017.
21. Patel R, **Chan PA**, Mena L, Crowley J, McCoy K, Nunn A. "Time to make the jump: Translating HIV pre-exposure prophylaxis research into real-world public health impact." *JAIDS*. April 4, 2017.
22. Arnold T, Brinkley-Rubinstein L, **Chan PA**, Perez-Brumer A, Bologna E, Beachamps L, Johnson K, Mena L, Nunn AS. "Social, Structural, Behavioral and Clinical Factors influencing Retention in Pre-Exposure Prophylaxis (PrEP) Care in Mississippi." *PLoS ONE*. 2017.
23. Cabral DJ, Wurster JI, Flokas ME, Alevizakos M, Zabat M, Korry BJ, Rowan AD, Sano WH, Andreatos N, Ducharme RB, **Chan PA**, **Mylonakis E**, **Fuchs BB**, Belenky P. The salivary microbiome is consistent between subjects and resistant to impacts of short-term hospitalization. *Sci Rep* 2017;7(1):11040. doi: 10.1038/s41598-017-11427-2. PMID: 28887570
24. Ross I, Mejia C, Melendez J, **Chan PA**, Nunn AS, Powderly W, Goodenberger K, Liu J, Mayer KH, Patel RR. "Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation." *PLoS One*. 2017 Mar 3;12(3).
25. Oldenburg CE, Nunn AS, Montgomery M, Almonte A, Mena L, Patel RP, Mayer KH, **Chan PA**. "Behavioral Changes Following Uptake of HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in a Clinical Setting." *AIDS and Behavior*. 2017 Feb 1.
26. Patel RR, Harrison LC, Patel VV, **Chan PA**, Mayer KH, Reno HE, Manning T. "HIV Pre-exposure Prophylaxis Programs Incorporating Social Applications Can Reach At-Risk Men Who Have Sex With Men for Successful Linkage to Care in Missouri, USA." *J Assoc Nurses AIDS Care*. 2017 Jan 17.
27. Nunn A, Brinkley-Rubinstein L, Rose J, Mayer K, Stopka T, Towey C, Harvey J, Santamaria K, Sabatino K, Trooskin S, **Chan PA**. "Latent class analysis of acceptability and willingness to pay for self-HIV testing in a United States urban neighbourhood with high rates of HIV infection." *J Int AIDS Soc*. 2017 Jan 17;20(1):1-9.
28. Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, Mayer KH, Mimiaga M, Patel R, **Chan PA**. "Defining the HIV Pre-Exposure Prophylaxis Care Continuum." *AIDS*. 2017 Jan 4.
29. Bertrand T, **Chan PA**, Howe K, Comella J, Marak T, Bandy U. "Health Equity, Social Justice, and HIV in Rhode Island: A Contemporary Challenge." *Rhode Island Medical Journal*. 2016 Nov; 99 (11): 21-24

30. **Chan PA**, Glynn TR, Oldenburg CE, Montgomery MC, Robinette AE, Almonte A, Raifman J, Mena L, Patel R, Mayer KH, Beauchamps LS, Nunn AS. "Implementation of Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention Among Men Who Have Sex With Men at a New England Sexually Transmitted Diseases Clinic." *Sex Transm Dis*. 2016 Nov;43(11):717-723.
31. Cunha BA, Baron J, **Cunha CB**: Once Daily High Dose Tigecycline (HDT): PK/PD Based Dosing for Optimal Clinical Effectiveness: Dosing Matters, Revisited. *Expert Review of Anti-infective Therapy* 22:1-11, 2016
32. Cunha BA, **Cunha CB**. Viral and Mycoplasmal Pneumonias.  
In: Bope ET, Kellerman RD (eds.): *Conn's Current Therapy 2016*  
Elsevier, New York, 2016
33. Cunha BA, **Cunha CB**, Lam B, Giuga J, Chin J, Zafonte VF, Gerson S: Nitrofurantoin Effectiveness in Treating Acute Uncomplicated Cystitis (AUC) in Hospitalized Adults with Renal Insufficiency: Antibiotic Stewardship Implications. *European Journal of Clinical Microbiology & Infectious Diseases* 36:1213-1216, 2017
34. **Cunha CB**, Cunha BA: Legionnaire's Disease and Its Protean Clinical Manifestations: The Ongoing Challenges of the Most Interesting Atypical Pneumonia. *Infectious Disease Clinics of North America* 31: xiii-xvi, 2017
35. **Cunha CB**, Cunha BA: Legionnaire's Disease Since Philadelphia: Lessons Learned and Continued Progress. *Infectious Disease Clinics of North America* 31:1-5, 2017
36. Cunha BA, **Cunha CB**: Legionnaire's Disease: A Clinical Diagnostic Approach. *Infectious Disease Clinics of North America* 31:81-93, 2017
37. **Cunha CB**, Cunha BA: Antimicrobial Therapy of Legionnaire's Disease: Antibiotic Stewardship Implications. *Infectious Disease Clinics of North America* 31:179-191, 2017
38. Cunha BA, **Cunha CB**: Legionnaire's Disease and its Mimics: A Clinical Perspective. *Infectious Disease Clinics of North America* 31:95-109, 2017
39. **Cunha CB**, Cunha BA. Rash and Fever.  
In: Vincent JL, Abraham E, Moore FA, Kochanek PM, Fink MP (eds.):  
*Textbook of Critical Care*, (7<sup>th</sup> Edition). Elsevier, New York, 2017
40. Cunha BA, Hage JE, Schoch PE, **Cunha CB**, Bottone EJ, Torres DC.  
Overview of Antimicrobial Therapy.  
In: Cunha CB, Cunha, BA (eds.): *Antibiotic Essentials* (15<sup>th</sup> Edition).  
Jaypee Brothers Medical Publishers Ltd, New Delhi, 2017
41. Cunha BA, Bruschi JL, Nichols RL, Papanicolaou G, Hage JE, Koff RS, Rex JH, Cleri DJ, **Cunha CB**, Fischer SA, Schlossberg D.  
Empiric Therapy Based on Clinical Syndrome.

- In: Cunha CB, Cunha BA (eds.): *Antibiotic Essentials* (15<sup>th</sup> Edition).  
Jaypee Brothers Medical Publishers Ltd, New Delhi, 2017
42. Cunha BA, Torres DC, Hage JE, Kubiak DW, Mickail N, Gran A, Munoz-Gomez S, **Cunha CB**, Rex JH, Kaplan MH, Parente DG, Fortin R. Antimicrobial Drug Summaries.  
In: Cunha CB, Cunha BA (eds.): *Antibiotic Essentials* (15<sup>th</sup> Edition).  
Jaypee Brothers Medical Publishers Ltd, New Delhi, 2017
  43. Cunha BA, **Cunha CB**. Viral and Mycoplasmal Pneumonias.  
In: Bope ET, Kellerman RD (eds.): *Conn's Current Therapy 2017*  
Elsevier, New York, 2017
  44. **Cunha CB**, Cunha BA. Babesiosis.  
In: Bope ET, Kellerman RD (eds.): *Conn's Current Therapy 2017*  
Elsevier, New York, 2017
  45. **Cunha CB**. Principles of Stewardship.  
In: LaPlante K, Cunha C, Morrill H, Rice L, Mylonakis E (eds.):  
*Antimicrobial Stewardship: Principles & Practice*  
CABI Publishers, London, 2017
  46. **Cunha CB**. Pharmacoeconomic Implications of Antimicrobial Adverse Events.  
In: LaPlante K, Cunha C, Morrill H, Rice L, Mylonakis E (eds.):  
*Antimicrobial Stewardship: Principles & Practice*  
CABI Publishers, London, 2017
  47. **Cunha CB**, Cunha BA. The Gram Stain Re-Visited: Importance in Antibiotic Stewardship Programs.  
In: Khardori N: *Bench to Bedside: Diagnostic Microbiology for the Clinician*.  
CRC Press, Boca Raton, 2017
  48. Orang'o O, Liu T, Christoffersen-Deb A, Itsura P, Oguda J, Washington S, Chumba D, Pisharodi L, **Cu-Uvin S**, Rositch AF. Use of VIA, Pap smear, or HR-HPV testing in women living with HIV/AIDS for post-treatment cervical cancer screening; same tests, different priorities. (2016) *AIDS*. Nov 7. [Epub ahead of print]. PMID: 27831951.
  49. Jais M, Younes N, Chapman S, **Cu-Uvin S**, Ghosh M. Reduced Levels and Bioactivity of Endogenous Protease Cathepsin D in Genital Tract Secretions of Postmenopausal Women. (2017) *AIDS Res Hum Retroviruses*. May; 33(5): 407-9. PMID: 2790371
  50. Omenge Orang'o E, Liu T, Christoffersen-Deb A, Itsura P, Oguda J, Washington S, Chumba D, Pisharodi L, **Cu-Uvin S**, Rositch AF. Use of visual inspection with acetic acid, Pap smear, or High-Risk Human papillomavirus testing in women living with HIV/AIDS for posttreatment cervical cancer screening; same tests, different priorities. (2017) *AIDS*. Jan 14; 31(2):233-240. PMID: 28002084

51. Adam GP, Di M, **Cu-Uvin S**, Halladay C, Smith BT, Trikalinos TA. Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: An evidence map. (2016) Rockville (MD): *Agency for Healthcare Research and Quality (US)* Nov. Report No: 16(17) – ECH040-EF. PMID: 27929614
52. Araos R, Montgomery V, Ugalde JA, Snyder GM, **D'Agata EMC**. Microbial disruption indices to detect colonization with multidrug-resistant organisms. *Infection Control and Hospital Epidemiology* 2017;38:1312-8.
53. Alevizakos M, **Farmakiotis D**, **Mylonakis E**. Updated practice guidelines for the diagnosis and management of aspergillosis: challenges and opportunities. *J Thor Dis* 2016;8(12):E767-70.
54. Black RC Jr, Taliano R, Reagan J, **Farmakiotis D**. Rhomboid glossitis in disseminated CMV infection. *IDCases* 2017;8:42-4.
55. Le A, **Farmakiotis D**, Tarrand JJ, Kontoyiannis DP. Initial treatment of cancer patients with fluconazole susceptible dose-dependent *Candida glabrata* fungemia: Better outcome with an echinocandin or polyene compared to an azole? *Antimicrob Agents Chemother* 2017;61(8):e00631-17.
56. **Farmakiotis D**, Kontoyiannis DP. Epidemiology of human pathogenic yeast antifungal resistance: Current viewpoint and practical recommendations for management. *Int J Antimicrob Agents* 2017; 50(3): 318-24.
57. Stone JA, Knoll B, **Farmakiotis D**. Relapsing EBV encephalitis in a renal transplant recipient. *IDCases* 2017;10:83-7.
58. Le A, Chung M, Pisharodi L, Reagan JL, **Farmakiotis D**. Photo Quiz: Dysuria in a patient with AIDS and lymphoma. *Clin Infect Dis* 2017; 65(5):867-9.
59. **Farmakiotis D**, Ross J, Koo S. Chapter 201: *Candida* and *Aspergillus*. In: McKean SC, Ross JJ, Dressler DD, Scheurer DB (Editors). *Principles and Practice of Hospital Medicine*, 2<sup>nd</sup> Edition, 2017. McGraw-Hill. pp. 1618-24.
60. Casadevall A, Cox EG, Del Poeta M, **Farmakiotis D**, Pappas PG, Zhang J. Rise in antifungal resistance may portend global health crisis. *Infectious Diseases in Childhood Cover Story* (by Sherrer K), November 2016; <http://www.healio.com/pediatrics/emerging-diseases/news/print/infectious-diseases-in-children/%7B205d68c3-bc8a-4b4b-83e2-5b1f70604874%7D/rise-in-antifungal-resistance-may-portend-global-health-crisis?page=4>.
61. Tabb Z, Moriarty K, Schrier MW, Amekah E, **Flanigan TP**, Lartey M. Assessing acceptability and feasibility of provider-initiated HIV testing and counseling in Ghana. (2017) *R I Med J*. Aug 1; 100(8): 19-22. PMID: 28759895
62. Johnston T, Hendricks G, Shen S, Chen R, Kwon B, Kelso, M, Kim W, **Fuchs BB**, **Mylonakis E**. Raf-kinase Inhibitor GW5074 shows antibacterial activity against methicillin

resistant *Staphylococcus aureus* and potentiates the activity of gentamicin. *Future Med Chem.* 2016;8(16):1941-1952. PMID: 27652456

63. Rossoni RD, **Fuchs BB**, de Barros PP, dos Santos Velloso M, Cardoso OC, Junqueira JC, **Mylonakis E**. *Lactobacillus paracasei* modulates the immune system of *Galleria mellonella* and protects against *Candida albicans* infection. *PLoS ONE.* 2017;12(3):e0173332. PMID: 28267809
64. Tharmalingam N, Jayamani E, Rajamuthiah R, Castillo D, **Fuchs BB**, Kelso MJ, **Mylonakis E**. Activity of a novel protonophore against methicillin-resistant *Staphylococcus aureus*. *Future Med Chem.* 2017;9(12):1401-1411. PMID: 28771026
65. Zheng Z, Tharmalingam N, Liu Q, Jayamani E, Kim W, **Fuchs BB**, Zhang R, Vilcinskis A, **Mylonakis E**. The synergistic efficacy of *Aedes aegypti* antimicrobial peptide cecropin A2 and tetracycline against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemoter.* 2017;61(7). pii: e00686-17. PMID: 28483966
66. Carter K, Gabrellas A, Shah S, **Garland JM**. “Improved Latent Tuberculosis Therapy Completion Rates in Refugee Patients Through Use of a Clinical Pharmacist.” *Int J Tuberculosis and Lung Disease:* 2017. 21(4):432-437. doi: 10.5588/ijtld.16.0575.
67. Taliano R, Godfrey M, **Garland JM**, Taylor LE, Cu-Uvin S, Resnick MB. “The Great Mimicker Strikes Again: An Unusual Case of Syphilitic Hepatitis with Marked Sinusoidal Histiocytic Infiltrate.” *AJSP: Reviews & Reports:* 2017. 22(3):143-145. doi: 10.1097/PCR.0000000000000196
68. J Gregson, P Kaleebu, V Marconi, C van Vuuren, N Ndemi, R Hamers, P Kanki, C Hoffmann, S Lockman, D Pillay, T de Oliveira, N Clumeck, G Hunt, B Kerschberger, R Shafer, C Yang, E Raizes, **R Kantor**, RK Gupta. Occult drug resistance to thymidine analogues and multidrug resistant HIV-1 following failure of first line tenofovir-based antiretroviral regimens in sub Saharan Africa: a retrospective multicenter cohort study. *Lancet Infectious Diseases* 2016 Nov 30 [Epub ahead of print]. PMID 27914856.
69. S Saravanan, B Kausalya, S Gomathi, S Sivamalar, B Pachamuthu, P Selvamuthu, A Pradeep, S Sunil, SN Mothi, DM Smith, **R Kantor**. Etravirine and Rilpivirine drug resistance among HIV-1 subtype C infected Children failing non -nucleoside reverse transcriptase inhibitor-based regimens in South India. *AIDS Research in Human Retroviruses* 2016 Dec 23 [Epub ahead of print]. PMID 27869478.
70. T Liu, JW Hogan, M Daniels, M Coetzer, Y Xu, G Bove, AK Delong, L Ledingham, M Orido, L Diero, **R Kantor**. Marker-Assisted Deconvolution of Pooled HIV-1 Viral Load Testing Improves Antiretroviral Treatment Monitoring Capacity. *Journal of AIDS* 2017;75:580-87. PMID 28489730.
71. R Paredes, P Tzou; G van Zyl, G Barrow, R Camacho, S Carmona, P Grant, R Gupta, R Hamers, PR Harrigan, M Jordan, **R Kantor**, DA Katzenstein, DR Kuritzkes, F Maldarelli, D Otelea, CL Wallis, JM Schapiro, RW Shafer. Collaborative Update of a Rule-Based

Expert System for HIV-1 Genotypic Resistance Test Interpretation. *PLOS One* 2017;12:e0181357. PMID 28753637.

72. SY Rhee, V Varghese, SP Holmes, G Van Zyl, K Steegen, MA Boyd, DA Cooper, S Nsanzimana, S Saravanan, C Charpentier, T de Oliveira, MA Etiebet, F Garcia, D Goedhals, P Gomes, HF Günthard, RL Hamers, CJ Hoffmann, G Hunt, A Jiamsakul, P Kaleebu, P Kanki, **R Kantor**, B Kerschberger, VC Marconi, J Ndahimana, N Ndembu, N Ngo-Giang-Huong, C Rokx, MM Santoro, JM Schapiro, D Schmidt, L Seu, KC Sigaloff, S Sirivichayakul, L Skhosana, H Sunpath, M Tang, C Yang, S Carmona, RK Gupta, RW Shafer. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. *EBioMedicine* 2017;18: 225-35. PMID 28365230.
73. HA Duarte, N Panpradist, IA Beck, B Lutz, J Lai, R Kanthula, **R Kantor**, A Tripathi, S Saravanan, I MacLeod, MH Chung, G Zhang, C Yang, LM Frenkel. Current status of point-of-care testing for HIV drug resistance. *Journal of Infectious Diseases* 2017;216(suppl 9):S824-S828. PMID 29040621.
74. C Godfrey, M Bobkova, C Boucher, G Ravasi, P Chen, F Zhang, Y Wu, **R Kantor**. Regional challenges in HIV drug resistance. *Journal of Infectious Diseases* 2017;216(suppl 9):S816-S819. PMID 28968824.
75. M Coetzer, L Ledingham, L Diero, E Kemboi, M Orido, **R Kantor**. Gag and gp41 amino acids linked to HIV-1 Protease Inhibitor Based 2<sup>nd</sup>-line Failure in HIV-1 subtype A from Western Kenya. *Journal of the International AIDS Society* 2017;20: 20:e25024. PMID 29098809.
76. Gamarel KE, Westfall AO, **Lally MA**, Hosek S, Wilson CM; Adolescent Medicine Trials Network for HIV/AIDS Intervention. Tobacco Use and Sustained Viral Suppression in Youth Living with HIV. *AIDS Behav.* 2017 Sep 26. doi: 10.1007/s10461-017-1915-2. [Epub ahead of print] PMID: 28951979
77. Barker DH, Nugent NR, Delgado JR, Knopik VS, Brown LK, **Lally MA**, McGearry JE. A genetic marker of risk in HIV-infected individuals with a history of hazardous drinking. *AIDS Care.* 2017 Sep;29(9):1186-1191. doi: 10.1080/09540121.2017.1291898. Epub 2017 Feb 21. PMID:28278565
78. Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, **Lally M**, Mayer KH, Anderson P, Kiser J, Rooney JF, Wilson CM; An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. Adolescent Trials Network (ATN) for HIV/AIDS Interventions. *J Acquir Immune Defic Syndr.* 2017 Jan 1;74(1):21-29. PMID: 27632233
79. Luther MK, **Mermel LA**, LaPlante KL. In vitro activity of linezolid and vancomycin against biofilm-producing *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Enterococcus faecalis* in a central venous catheter model. *Am J Health-Syst Pharm* 60:3178-3182, 2016.



80. Smit MA, Rasinski KA, Braun BI, Kusek LL, Milstone AM, Morgan DJ, **Mermel LA**. Ebola preparedness resources for acute care hospitals in the United States: a cross-sectional study of costs, benefits and challenges. *Infect Control Hosp Epidemiol* 38:405-410, 2017.
81. Chow EJ, **Mermel LA**. Hospital-acquired respiratory viral infections: incidence, morbidity and mortality in pediatric and adult patients. *Open Forum Infect Dis* 4(1):ofx006. doi: 10.1093/ofid/ofx006. eCollection 2017.
82. Morrill HJ, Morton JB, Caffrey AR, Jiang L, Dosa D, **Mermel LA**, LaPlante KL. Antimicrobial resistance of Escherichia coli urinary isolates in the Veterans Affairs Healthcare System. *Antimicrob Agents Chemother* 61(5). pii: e02236-16, 2017.
83. Luther MK, **Mermel LA**, LaPlante KL. Comparison of linezolid and vancomycin lock solutions with and without heparin against biofilm-producing bacteria. *Am J Health Syst Pharm* 74(9):e193-e201, 2017.
84. Doberstein C, Abass N, Choi D, Smith J, Groh D, **Mermel LA**, Doberstein C. Cerebral epidural abscess secondary to Blastomyces masquerading as an epidermoid tumor. *Open Forum Infect Dis* doi.org/10.1093/ofid/ofx112.
85. **Mermel LA**. Short-term peripheral venous catheter-related bloodstream infections: a systematic review. *Clin Infect Dis* 65:1757–1762, 2017.
86. Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Easom AM, Mokrzycki MH, Newcomb B, Patel PR, **Mermel LA**, Chand D. Recommended clinical trial endpoints for catheters. *Clin J Am Soc Nephrol* July 20, 2017. pii: CJN.12011116. doi: 10.2215/CJN.12011116. [Epub ahead of print].
87. **Mermel LA**. Do patients get whacked when hospitals get HACed? (letter)? *Infect Control Hosp Epidemiol* 38:249-250, 2017.
88. Harris D, Cooper E, Vanner C, **Mermel LA**. Respiratory viral testing in laboratories serving acute care hospitals in Rhode Island. *Med Health RI* 100:29-30, 2017.
89. Detsis M, Karanika S, **Mylonakis E**. ICU Acquisition rate, risk factors and clinical significance of digestive tract colonization with ESBL-producing Enterobacteriaceae: A systematic review and meta-analysis. *Crit Care Med*. 2017;45(4):705-714. PMID: 28157141
90. Alevizakos M, Gaitanidis A, Nasioudis D, Tori K, Flokas M, **Mylonakis E**. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: A systematic review and meta-analysis. *Open Forum Infect Dis*. 2016;4(1):ofw246. PMID: 28480243

91. Andreatos N, Zacharioudakis IM, Zervou FN, Muhammed M, **Mylonakis E**. Discrepancy between financial disclosures of authors of clinical practice guidelines and reports by industry. *Medicine[Baltimore]* 2017;96(2):e5711. PMID: 28079800
92. Flokas M, Karanika S, Alevizakos M, **Mylonakis E**. Prevalence of ESBL-producing Enterobacteriaceae in pediatric bloodstream infections: A systematic review and meta-analysis. *PLoS ONE*. 2017;12(1):e0171216. PMID: 28141845
93. Karanika S\*, Grigoras C\*, Flokas M, Alevizakos M, Kinamon T, Kojic M, **Mylonakis E**. The attributable burden of *Clostridium difficile* infection to long-term care facilities stay: A clinical study. *J Am Geriatr Soc*. 2017;65(8):1733-1740. PMID: 28306141
94. Alevizakos M, Kallias A, Flokas M, **Mylonakis E**. Colonization with ESBL-producing Enterobacteriaceae and risk for infection in solid organ transplantation: A review and meta-analysis. *Transpl Infect Dis*. 19(4). doi: 10.1111/tid.12718. Epub 2017 Jun 20. PMID: 28470983
95. Detsis M, Tsioutis C, Karageorgos SA, Sideroglou T, Hatzakis A, **Mylonakis E**. Factors associated with HIV testing and HIV treatment adherence: A systematic review. *Curr Pharm Des*. 2017;23(18):2568-2578. PMID: 283456038
96. Flokas ME, Karageorgos SA, Detsis M, Alevizakos M, **Mylonakis E**. Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-analysis. *Int J Antimicrob Agents* 2017; 49(5):565-572. PMID: 28336313
97. Kim W, Hendricks GL, Lee K, **Mylonakis E** An update on *C. elegans* for preclinical drug discovery. *Expert Opin Drug Discov*. 2017;12(6):625-633. PMID: 28402221.
98. Alevizakos M, Nasioudis D, **Mylonakis E** Urinary tract infections due to ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis. *Transpl Infect Dis*. 2017 Aug 13. doi: 10.1111/tid.12759. [Epub ahead of print] PMID: 28803446
99. Muhammed M, Flokas ME, Detsis M, Alevizakos M, **Mylonakis E**. Comparison between carbapenems and beta-lactam/beta-lactamase inhibitors in the treatment for bloodstream infections caused by ESBL-producing Enterobacteriaceae: A systematic review and meta-analysis. *Open Forum Infect Dis*. 2017;4(2):ofx099. doi: 10.1093/ofid/ofx099. PMID: 28702469
100. Gwisai T, Hollingsworth NR, Cowles S, Tharmalingam N, **Mylonakis E**, **Fuchs BB**, Shukla A. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections. *Biomed Mater*. 2017;12(4):045010. doi: 10.1088/1748-605X/aa7105. PMID: 28471351
101. Andreatos N, Flokas ME, Apostolopoulou A, Alevizakos M, **Mylonakis E**. The dose-dependent efficacy of cefepime in the empiric management of febrile neutropenia: A

- systematic review and meta-analysis. *Open Forum Infect Dis.* 2017;4(3):ofx113. doi: 10.1093/ofid/ofx113. PMID: 28761897
102. Joyce NR, **Mylonakis E**, Mor V. Effect of *Clostridium difficile* prevalence in hospitals and nursing homes on risk of infection. *J Am Geriatr Soc.* 2017;65(7):1527-1534. PMID: 28394408
  103. Johann S, Sá N, de Lima C, Lino CI, Barbeira P, Baltazar L, Santos D, Oliveira R, **Mylonakis E.**, **Fuchs BB.** Heterocycle thiazole compounds exhibit antifungal activity through increase in the production of reactive oxygen species in *Cryptococcus neoformans/Cryptococcus gattii* species complex. *Antimicrob Agents Chemoter.* 2017;61(8). pii: e02700-16. doi: 10.1128/AAC.02700-16. PMID: 28533240
  104. Alevizakos M, **Mylonakis E** Colonization and infection with extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in patients with malignancy *Expert Rev Anti Infect Ther.* 2017;15(7):653-661. PMID: 28659026
  105. Sartelli M, [...], **Mylonakis E**, [...], Catena F. The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. *World J Emerg Surg.* 2017 Aug 1;12:34. doi: 10.1186/s13017-017-0145-2. PMID: 28775763
  106. Xiao X, Feng J, Li Y, Chen Z, Shi M, Xi L, **Mylonakis E**, Zhang J. *Agrobacterium tumefaciens*-mediated transformation: an efficient tool for targeted gene disruption in *Talaromyces marneffeii*. *World J Microbiol Biotechnol.* 2017;33(10):183. doi: 10.1007/s11274-017-2352-0. PMID: 28948456
  107. Li M; Lee K; Hsu M; **Nau G; Mylonakis E; Ramratnam B;** Lactobacillus-derived extracellular vesicles enhance host immune responses against vancomycin-resistant enterococci. *BMC Microbiol.* 2017 Mar 14;17(1):66 PMID: 28288575
  108. Jayamani E, Tharmalingam N, Rajamuthiah R, Coleman JJ, Kim W, Okoli I, Hernandez AM, Lee K, **Nau GJ**, Ausubel FM, **Mylonakis E.** Characterization of a *Francisella tularensis*-*Caenorhabditis elegans* pathosystem for the evaluation of therapeutic compounds. *Antimicrob Agents Chemoter.* 2017;61(9). pii: e00310-17. PMID: 28652232
  109. **Noska A**, Roberts M, Stein L, Sufirin C, **Beckwith C, Rich J**, Dauria E, Clarke J. History of sex exchange in women with a history of incarceration. *J of Health Care for the Poor and Underserved.* 2016;27(2A):149-62. PMID: 27133516
  110. Tsai J, Yakovchenko V. Jones N, Skolnik A. **Noska A**, Gifford AL, McInnes DK. “Where’s my choice?” An examination of veteran and provider experiences with hepatitis C treatment through the Veterans affairs Choice Program. *Med Care.* 2017 Mar. doi: 10.1097/MLR.0000000000000706. [Epub ahead of print]

111. **Noska AJ**, Belperio PS, Loomis TP, O'Toole TP, Backus LI. Engagement in the hepatitis C care cascade among homeless veterans, 2015. *Public Health Rep.* 2017 Jan 1;33354916689610. doi: 10.1177/0033354916689610. [Epub ahead of print]
112. **Noska AJ**, Belperio PS, Loomis TP, O'Toole TP, Backus LI. Prevalence of HIV, HCV, HBV among homeless and non-homeless United States veterans. *Clin Infect Dis.* 2017 Apr 1. doi: 10.1093/cid/cix295. [Epub ahead of print]
113. Rogers R, Goh R, **Noska A**. Increased risk for urothelial cell carcinoma after BK polyomavirus infection in kidney transplant recipients: a cohort study of veterans. *Transpl Infect Dis.* 2017 Oct;19(5). doi: 10.1111/tid.12752. Epub 2017 Sep 16.
114. Mao G, **Ramratnam B**. The Clinical Research Landscape in Rhode Island. *R I Med J* (2013). 2017 Jan 6;100(1):42-46. PMID: 28060965
115. Jamwal R, Topletz AR, **Ramratnam B**, Akhlaghi F; Ultra-performance Liquid Chromatography Tandem Mass-Spectrometry (UPLC-MS/MS) for Simple and Simultaneous Quantification of Cannabinoids, THC, CBD, 11-OH THC and THC-COOH, in Human Plasma. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2017 Mar 24;1048:10-18. PMID: 28192758
116. Cheruiyot C, Pataki Z, Williams R, **Ramratnam B**, Li M. SILAC Based Proteomic Characterization of Exosomes from HIV-1 Infected Cells. *J Vis Exp.* 2017 Mar 3;(121). PMID: 28287540
117. Mao G, **Ramratnam B**. National Institutes of Health Funding in Rhode Island. *R I Med J* (2013). 2017 Jul 5;100(7):22-26. PMID: 28686236
118. Monnig, M.A., Kahler, C.W., Cioe, P.A., Monti, P.M., Mayer, K.H., Pantalone, D.W., Cohen, R.A., & **Ramratnam, B**. Markers of microbial translocation and immune activation predict cognitive processing speed in heavy-drinking men living with HIV. *Microorganisms.* 2017 Sep 21;5(4) PMID: 28934108
119. Fiorito T, **Reece RM**. *Borrelia Miyamotoi* PCR positivity on a tick-borne disease panel in an endemic region of Rhode Island: a case series. (2017) *Infect Dis Clin Pract.* Sept; 25(5):250-254. doi 10.1097/IPC.0000000000000509
120. **Reece RM**, Norman B, Kwara A, **Flanigan T**, Rana A. Retention to Care of HIV-Positive Postpartum Females in Kumasi, Ghana. (2016) *J Int Assoc Provid AIDS Care.* Sep; 15(5):406-11. PMID: 26319433. PMCID: PMC4811741
121. Moriarty K, Genberg B, Norman B, **Reece RM**. The effect of antiretroviral stock-outs on medication adherence among patients living with HIV in Ghana: a qualitative study. (2017) *J Assoc Nurses AIDS Care.* Oct 9; doi <https://doi.org/10.1016/j.jana.2017.09.014>

122. **Reece RM**, Smit M, **Flanigan T**. Ebola Virus. In: Encyclopedia of Immunobiology, Vol 4 pages 355-63. Oxford Academic Press. Immunity to Viral Infections. (Chapter 14027). 2016
123. Garcia-Solache, M., Lebreton, F., McLaughlin, R.E., Whitaker, J.D., Gilmore, M.S., **Rice, L.B.** Homologous recombination with large chromosomal regions facilitates acquisition of  $\beta$ -lactam and vancomycin resistance in *Enterococcus faecium*. *Antimicrob Agents Chemother* 23: 5777-86 2016
124. Hugonnet JE, Mengin-Lecreulx D, Monton A, den Blaauwen T, Carbonnelle E, Veckerlé C, Brun YV, van Nieuwenhze M, Bouchier C, Tu K, **Rice LB**, Arthur M. Factors essential for L,D-transpeptidase-mediated peptidoglycan cross-linking and  $\beta$ -lactam resistance in *Escherichia coli*. *Elife*, October 21 2016
125. Miller, W.R., Murray, B.E., **Rice, L.B.**, Arias, C.A., Vancomycin-resistant enterococci: therapeutic challenges in the 21<sup>st</sup> century. *Inf Dis Clin North Am*. 30: 415-39 2016
126. **Rice L.B.** Acknowledgement of Ad Hoc Reviewers. *Antimicrob Agents Chemother* 60(12):7007-7014, 2016.
127. Gordon MS, Crable EL, Carswell SB, Leopold J, Hodo-Powell J, McKenzie M, **Rich JD**. A Randomized Controlled Trial of Intensive Case Management (Project Bridge) for HIV-Infected Probationers and Parolees. *AIDS Behav*. 2017 Dec 22. doi: 10.1007/s10461-017-2016-y. [Epub ahead of print] PMID: 29273946
128. Marshall BDL, Krieger MS, Yedinak JL, Ogera P, Banerjee P, Alexander-Scott NE, **Rich JD**, Green TC. Epidemiology of fentanyl-involved drug overdose deaths: A geospatial retrospective study in Rhode Island, USA. *Int J Drug Policy*. 2017 Aug;46:130-135. doi: 10.1016/j.drugpo.2017.05.029. Epub 2017 Jun 7. PubMed PMID: 28601512.
129. Carroll JJ, Marshall BDL, **Rich JD**, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. *Int J Drug Policy*. 2017 Aug;46:136-145. doi: 10.1016/j.drugpo.2017.05.023. Epub 2017 Jun 1. PubMed PMID: 28578864.
130. Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, **Rich JD**, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. *Subst Abuse Treat Prev Policy*. 2017 May 16;12(1):24. doi: 10.1186/s13011-017-0107-4. PubMed PMID: 28511680; PubMed Central PMCID: PMC5433052.
131. Beaudoin FL, **Rich JD**. Opioid Prescribing by Emergency Physicians and Risk of Long-Term Use. *N Engl J Med*. 2017 May 11;376(19):1895-6. doi: 10.1056/NEJMc1703338. PubMed PMID: 28492072.

132. Christopher PP, Garcia-Sampson LG, Stein M, Johnson J, **Rich J**, Lidz C. Enrolling in Clinical Research While Incarcerated: What Influences Participants' Decisions? *Hastings Cent Rep.* 2017 Mar;47(2):21-29. doi: 10.1002/hast.686. PubMed PMID: 28301701; PubMed Central PMCID: PMC5356487.
133. Brinkley-Rubinstein L, Cloud DH, Davis C, Zaller N, Delany-Brumsey A, Pope L, Martino S, Bouvier B, **Rich J**. Addressing excess risk of overdose among recently incarcerated people in the USA: harm reduction interventions in correctional settings. *Int J Prison Health.* 2017 Mar 13;13(1):25-31. doi: 10.1108/IJPH-08-2016-0039. PubMed PMID: 28299971.
134. Claborn K, Becker S, Ramsey S, **Rich J**, Friedmann PD. Mobile technology intervention to improve care coordination between HIV and substance use treatment providers: development, training, and evaluation protocol. *Addict Sci Clin Pract.* 2017 Mar 14;12(1):8. doi: 10.1186/s13722-017-0073-1. PubMed PMID: 28288678; PubMed Central PMCID: PMC5348772.
135. Kobayashi L, Green TC, Bowman SE, Ray MC, McKenzie MS, **Rich JD**. Patient Simulation for Assessment of Layperson Management of Opioid Overdose With Intranasal Naloxone in a Recently Released Prisoner Cohort. *Simul Healthc.* 2017 Feb;12(1):22-27. doi: 10.1097/SIH.000000000000182. PubMed PMID: 28146450; PubMed Central PMCID: PMC5300264.
136. Smith JM, **Rich JD**. Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs. *Hepatology.* 2017 Jun;65(6):2129. doi: 10.1002/hep.29070. Epub 2017 Apr 24. PubMed PMID: 28108982.
137. **Rich JD**, **Beckwith CG**, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, Amon JJ, Milloy MJ, King MRF, Sanchez J, Atwoli L, Altice FL. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. *Lancet.* 2016 Sep 10; 388(10049):1103-1114. doi: 10.1016/S0140-6736(16)30379-8. Epub 2016 Jul 14. Review. PubMed PMID: 27427452; PubMed Central PMCID: PMC5504684.
138. Coffin P, **Rich J**, Dailey M, Stancliff S, Beletsky L. While we dither, people continue to die from overdose: Comments on 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?' *Addiction.* 2016 Oct;111(10):1880-1. doi: 10.1111/add.13412. Epub 2016 Jul 14. PubMed PMID: 27412566; PubMed Central PMCID: PMC5510754.
139. Aibana O, Bachmaha M, Krasiuk V, **Rybak N**, **Flanigan TP**, Petrenko V, Murray MB. Risk factors for poor multi-drug resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. (2017) *BMC Infect Dis.* Feb 7; 17(1):129. PMID: 28173763. PMCID: PMC5294867
140. McGill F, Heyderman RS, Panagiotou S, **Tunkel AR**, Solomon T. Acute bacterial meningitis in adults. *Lancet* 2016;388:3036-3047. [http://dx.doi.org/10.1016/S0140-6736\(16\)30654-7](http://dx.doi.org/10.1016/S0140-6736(16)30654-7).

141. **Tunkel AR**, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, van de Beek D, Bleck TP, Garton HJL, Zunt JR. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. *Clin Infect Dis* 2017;64:e34-e65. DOI: 10.1093/cid/ciw861.
142. McCance-Katz EF, George P, Alexander Scott N, Dollase R, **Tunkel AR**, McDonald J. Access to treatment for opioid use disorders: medical student preparation. *Am J Addict* 2017;26:316-318. DOI: 10.1111/ajad.12550.
143. **Tunkel AR**, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, van de Beek D, Bleck TP, Zunt JR. Reply to Marx et al. Vancomycin MIC is not a substitute for clinical judgment: response to the healthcare-associated ventriculitis and meningitis. *Clin Infect Dis* 2017;65:1429-1430.
144. **Tunkel AR**. Aseptic meningitis in adults. In: UpToDate. Basow DS, ed. Waltham, MA. 2016.
145. Bloch KC, Glaser CA, **Tunkel AR**. Encephalitis and myelitis. In: Infectious Diseases, 4<sup>th</sup> ed. Cohen J, Powderly WG, Opal SM, eds. Philadelphia: Elsevier. 2017:189-197.
146. **Tunkel AR**, Winn HR, Scheld WM. Brain abscess. In: Youmans & Winn Neurological Surgery, 7<sup>th</sup> ed. Winn HR, ed. Philadelphia: Elsevier. 2017:e187-e204.
147. Hasbun R, **Tunkel AR**. Central nervous system infections in the elderly. In: Brain and Spine Surgery in the Elderly. Berhouma M, Krolak-Salmon P, eds. Switzerland: Springer. 2017:81-94.
148. **Tunkel AR**. Initial therapy and prognosis of bacterial meningitis in adults. In: UpToDate. Basow DS, ed. Waltham, MA. 2017.
149. **Tunkel AR**. Treatment of bacterial meningitis caused by specific pathogens in adults. In: UpToDate. Basow DS, ed. Waltham, MA. 2017.
150. **Tunkel AR**, Scheld WM. Brain and spinal abscesses. In: Scientific American Medicine [online]. Burakoff R, ed. Hamilton, ON: Decker International Properties; July 2017. DOI: 10.2310/7900.1304. Available at <http://www.sciammedicine.com>.
151. **Wing EJ**. HIV and Aging. *International Journal of Infect Diseases* 53:61-68, 2016 PMID27756578 Free full text
152. **Wing, E.J.** The Aging Population with HIV Infection. *Transactions of the American Clinical and Climatological Association* 128:131-141, 2017. PMID28790494 PMCID5525433 Free PMC Article
153. Becofsky K, **Wing EJ**, McCaffery J, Bodreau M, Wing RR. A Randomized, Controlled Trial of a Behavioral Weight Loss Program for HIV-Infected Patients. *Clinical Infectious Diseases* 65(1):154-7, 2017. Epub 3/23/17. PMID28369269